Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

Marie Skłodowska-Curie Action · Running

IMMERGE Storming Immune Monogenic Conditions through Multiomic and Gene Editing Approaches

Coordinator
Fundacio Institut De Recerca Contra La Leucemia Josep Carreras, Spain
Runs
1 January 2024 to 31 December 2027
Status
Running
EU funding
€2.6m
Total cost
—
Partners
29 organisations in 8 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101119927

What the project is doing

In the project's own words, from its summary on CORDIS.

The human immune system controls the efficiency to respond to infections and eliminate aberrant cells, such as cancer cells. Immune function depends on the balanced contribution of many genes, encoding for receptors, cytokines, cell signalling molecules and transcription factors and are modulated by a wide range of environmental and epigenetic factors. Monogenic mutations for immune-related genes, also known as Inborn Errors of Immunity (IEI), provide unique examples for understanding immune fitness.

IEI, individually considered as rare diseases, constitute a group of >400 immune disorders with a combined prevalence similar to leukemias (1/1,000-1/5,000). For a given mutated gene, IEI patients can display a wide range of phenotypic expressivity (from asymptomatic to severely impaired) and different responses to treatments. Therefore, there is an unmet need to address the wide underlying impact of IEI. Previous EU consortia have not addressed these questions in full.

It is therefore needed a new generation of researchers, equipped with a complete set of scientific, technological and strategic skills; and a wide vision to face the outstanding challenges in the IEI field. To this end, the IMMERGE MSCA DN combines the talent of leaders from different clinical and basic research and biotech environments to train 11 doctoral candidates. Through our research activity and training activities, we will address key challenges in the field: 1) To assess the functional impact of IEI in different immune cell types through single cell and bulk multiomics. 2) To develop computational tools for dissecting the altered cellular pathways underlying specific IEI. 3) To genetically correct or model IEI and develop pre-clinical models.

With our strategy, IMMERGE will generate an outstanding network of professionals able to develop impactful studies that will change the field, generate tools for personalised medicine and generate awareness in the society and influence policy makers.

Topics

Who is involved

OrganisationCityCountryRole
Fundacio Institut De Recerca Contra La Leucemia Josep CarrerasBadalonaSpainCoordinator
Fondazione per L'istituto Di Ricerca in BiomedicinaBellinzonaSwitzerlandAssociatedpartner
Universita Della Svizzera ItalianaLuganoSwitzerlandAssociatedpartner
Universitat BaselBaselSwitzerlandAssociatedpartner
Albert-Ludwigs-Universitaet FreiburgFreiburgGermanyAssociatedpartner
Deutsche Selbsthilfe Angeborene Immundefekte e. V.SchnaitseeGermanyAssociatedpartner
European Molecular Biology LaboratoryHeidelbergGermanyParticipant
EpiQMAx GmbHPlaneggGermanyAssociatedpartner
Leadership Sculptor GmbHBaden-BadenGermanyAssociatedpartner
Universitaetsklinikum FreiburgFreiburgGermanyParticipant
Onechain Immunotherapeutics S.l.BarcelonaSpainAssociatedpartner
Quantitative Genomic Medicine Laboratories SLEsplugues Del LlobregatSpainParticipant
Scienseed SLMadridSpainAssociatedpartner
Universidad Pompeu FabraBarcelonaSpainAssociatedpartner
Universitat De BarcelonaBarcelonaSpainAssociatedpartner
Centre National De La Recherche Scientifique CNRSParisFranceParticipant
Universite D'aix MarseilleMarseilleFranceAssociatedpartner
Hadassah Medical OrganizationJerusalemIsraelAssociatedpartner
Research Fund of the Hadassah Medical Organization (r.a)JerusalemIsraelParticipant
The Hebrew University of JerusalemJerusalemIsraelAssociatedpartner
Alia TherapeuticsMilanoItalyAssociatedpartner
Alia TherapeuticsMilanoItalyParticipant
Ospedale San Raffaele SRLMilanoItalyParticipant
Universita Degli Studi Di TrentoTrentoItalyAssociatedpartner
Universita Degli Studi Di TrentoTrentoItalyParticipant
Universita Vita-Salute San RaffaeleMilanoItalyAssociatedpartner
Olink Proteomics ABUppsalaSwedenAssociatedpartner
Genome Research Limited LbgSaffron WaldenUnited KingdomAssociatedpartner
The Chancellor Masters and Scholars of the University of CambridgeCambridgeUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI